<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556539</url>
  </required_header>
  <id_info>
    <org_study_id>QF-SC10914-201</org_study_id>
    <nct_id>NCT04556539</nct_id>
  </id_info>
  <brief_title>Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer</brief_title>
  <official_title>SC10914 Monotherapy for gBRCA1/2 Mutation Advanced Ovarian Cancer Patients With at Least 2 Prior Lines of Chemotherapy: a Single Arm, Open Label, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II, multicenter, open-label, single-arm study to evaluate the efficacy, safety and&#xD;
      pharmacokinetics of SC10914 in subjects with gBRCA1/2 mutated advanced ovarian cancer in&#xD;
      china.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 104 subjects with gBRCA1/2 mutated advanced ovarian cancer is planned to be&#xD;
      enrolled to observe the efficacy, safety and PK profile of SC10914.&#xD;
&#xD;
      The subjects oral administration SC10914 tablets 400mg on an empty stomach, three times a&#xD;
      day, for 28 consecutive days as a treatment cycle, until disease progression (PD) or the&#xD;
      toxicity was intolerable. PK blood samples are planned to be collected for each enrolled&#xD;
      subject on C1D28 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>up to 100 weeks (estimated)</time_frame>
    <description>assessed by the independent imaging assessment committee (recist1.1)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Advanced Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>SC10914 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SC10914</intervention_name>
    <description>400mg TID, oral admination on fasting condition</description>
    <arm_group_label>SC10914 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Sign informed consent voluntarily;&#xD;
&#xD;
          2. ≥18 years old;&#xD;
&#xD;
          3. Histologically confirmed ovarian epithelial cancer, fallopian tube cancer or primary&#xD;
             peritoneal cancer( high-grade carcinoma cancer or endometrioid carcinoma);&#xD;
&#xD;
          4. gBRCA1/2 mutation positive;&#xD;
&#xD;
          5. Had recived at least 2 prior lines of chemotherapy;&#xD;
&#xD;
          6. Platinum sensitive patients;&#xD;
&#xD;
          7. The last line of therapy befor enrollment failed；&#xD;
&#xD;
          8. ECOG≤2；&#xD;
&#xD;
        8. Had at least one measurable lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous treatment with PARP inhibitor;&#xD;
&#xD;
          2. Symptomatic brain metastases;&#xD;
&#xD;
          3. Large amount of fluid in the third gap；&#xD;
&#xD;
          4. Subjects with not enough organ functional reserve at baseline, which met at least one&#xD;
             of the following criteria： ANC&lt;1.5×10^9/L PLT&lt;100×10^9/L Hb&lt;100g/L TBIL&gt;1.5×ULN ALT,&#xD;
             AST&gt;2.5×ULN (without liver metastases) or ALT, AST&gt;5×ULN (with liver metastases) Cr&#xD;
             &gt;1.5×ULN&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liu chunlei</last_name>
    <phone>13911737489</phone>
    <email>liuchunlei@sh-qingfeng.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhang zhe</last_name>
    <phone>13115039707</phone>
    <email>zhangzhe@sh-qingfeng.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fujian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin An</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

